These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9248260)

  • 41. Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer.
    Higashi K; Nishikawa T; Seki H; Oguchi M; Nambu Y; Ueda Y; Yuasa K; Tonami H; Okimura T; Yamamoto I
    J Nucl Med; 1998 Jan; 39(1):9-15. PubMed ID: 9443730
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The clinical impact of integrated FDG PET-CT on management decisions in patients with lung cancer.
    Subedi N; Scarsbrook A; Darby M; Korde K; Mc Shane P; Muers MF
    Lung Cancer; 2009 Jun; 64(3):301-7. PubMed ID: 19004519
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
    Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Decision analysis for the cost-effective management of recurrent colorectal cancer.
    Park KC; Schwimmer J; Shepherd JE; Phelps ME; Czernin JR; Schiepers C; Gambhir SS
    Ann Surg; 2001 Mar; 233(3):310-9. PubMed ID: 11224617
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Cost-effective PET investigations in oncology].
    Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Galuska L; Trón L; Esik O
    Magy Onkol; 2002; 46(3):203-23. PubMed ID: 12368917
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Positron emission tomography in the evaluation of intrathoracic lymphatic extension of non-small cell bronchial cancer. A preliminary study of 30 patients].
    Bury T; Corhay JL; Paulus P; Weber T; D'Harcour JB; Limet R; Rigo P; Radermecker MF
    Rev Mal Respir; 1996 Jul; 13(3):281-6. PubMed ID: 8765921
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Accuracy of positron emission tomography with fluorine-18-fluoro-deoxyglucose].
    Hellwig D; Gröschel A; Rentz K; Sybrecht GW; Kirsch CM; Ukena D
    Pneumologie; 2001 Aug; 55(8):363-6. PubMed ID: 11505287
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Positron emission tomographic imaging with fluorodeoxyglucose isefficacious in evaluating malignant pulmonary disease.
    Graeber GM; Gupta NC; Murray GF
    J Thorac Cardiovasc Surg; 1999 Apr; 117(4):719-27. PubMed ID: 10096967
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of 18F-FDG PET/CT in the treatment of patients with non-small cell lung cancer.
    Taus Á; Aguiló R; Curull V; Suárez-Piñera M; Rodríguez-Fuster A; Rodríguez de Dios N; Pijuan L; Zuccarino F; Vollmer I; Sánchez-Font A; Belda-Sanchis J; Arriola E
    Arch Bronconeumol; 2014 Mar; 50(3):99-104. PubMed ID: 24360985
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the clinical diagnosis of lung cancer].
    Demura Y; Mizuno S; Wakabayashi M; Totani Y; Okamura S; Ameshima S; Ishizaki T; Miyamori I; Ito H; Yonekura Y
    Nihon Kokyuki Gakkai Zasshi; 2000 Sep; 38(9):676-81. PubMed ID: 11109804
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of 2-[18F]fluoro-2-deoxyglucose positron emission tomography in preoperative management of solid-type small-sized lung cancer.
    Saisho S; Yasuda K; Maeda A; Yukawa T; Okita R; Hirami Y; Shimizu K; Nakata M
    Ann Nucl Med; 2013 Jul; 27(6):515-22. PubMed ID: 23504519
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities.
    Lowe VJ; Hoffman JM; DeLong DM; Patz EF; Coleman RE
    J Nucl Med; 1994 Nov; 35(11):1771-6. PubMed ID: 7965154
    [TBL] [Abstract][Full Text] [Related]  

  • 54. FDG PET: advantages for staging the mediastinum?
    Franzius C
    Lung Cancer; 2004 Aug; 45 Suppl 2():S69-74. PubMed ID: 15552784
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET).
    Kut V; Spies W; Spies S; Gooding W; Argiris A
    Am J Clin Oncol; 2007 Feb; 30(1):45-50. PubMed ID: 17278894
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography.
    Flanagan FL; Dehdashti F; Siegel BA; Trask DD; Sundaresan SR; Patterson GA; Cooper JD
    AJR Am J Roentgenol; 1997 Feb; 168(2):417-24. PubMed ID: 9016218
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Detecting recurrent or residual lung cancer with FDG-PET.
    Inoue T; Kim EE; Komaki R; Wong FC; Bassa P; Wong WH; Yang DJ; Endo K; Podoloff DA
    J Nucl Med; 1995 May; 36(5):788-93. PubMed ID: 7738649
    [TBL] [Abstract][Full Text] [Related]  

  • 59. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management.
    Hetzel M; Arslandemir C; König HH; Buck AK; Nüssle K; Glatting G; Gabelmann A; Hetzel J; Hombach V; Schirrmeister H
    J Bone Miner Res; 2003 Dec; 18(12):2206-14. PubMed ID: 14672356
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer.
    Kamel EM; Zwahlen D; Wyss MT; Stumpe KD; von Schulthess GK; Steinert HC
    J Nucl Med; 2003 Dec; 44(12):1911-7. PubMed ID: 14660716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.